Matches in SemOpenAlex for { <https://semopenalex.org/work/W156942242> ?p ?o ?g. }
Showing items 1 to 61 of
61
with 100 items per page.
- W156942242 endingPage "54" @default.
- W156942242 startingPage "1045" @default.
- W156942242 abstract "The aim of our study is to report the most adequate therapy for prolactinoma in the cabergoline era. From 2003 to 2009, 27 patients with prolactinoma were treated at our hospital. Patients are categorized into 2 groups. The Cabergoline Group: Cabergoline was administered for 5 years and discontinued. Using this protocol, the case with normal prolactin level in addition to having no visible tumor more than 24 months after the discontinuation of cabergoline was judged as cured. The Operation Group: Transsphenoidal surgery (TSS) was performed first. In the Cabergoline group, 12 cases were cured with 5 years cabergoline treatment (Cure) and 6 cases were not cured (Not cure). We compared the pretreatment prolactin level, the normalization of the serum level of prolactin, the degree of invasiveness on MRI, regression of the tumor during treatment on MRI, max dose of cabergoline, degree of pituitary hormone replacement, frequency of pregnancy, and follow up periods between the Cabergoline-cure group, the Cabergoline-not-cure group, and the Operation group. Normalization rate in serum level of prolactin and cure rate were 91% and 63% in the Cabergoline group. Pretreatment prolactine level and the frequency of tumor invasiveness on initial MRI were significantly higher in the Cabergoline-not-cure group compared to the Cabergoline-cure group. All of the five woman accompanied with pregnancy after the treatment belonged to the Cabergoline-cure group. In the Operation group, all 4 cases achieved normalization of serum prolactin level without visible tumor and with normal pituitary function. Cabergoline for prolactinoma is effective, but the cure rate by continuous usage of cabergoline for 5 years was 67%. The factors that cabergoline and / or TSS can cure prolactinoma are non-invasive tumor and prolactin level under 200 ng/mL at pretreatment." @default.
- W156942242 created "2016-06-24" @default.
- W156942242 creator A5005698071 @default.
- W156942242 creator A5016298609 @default.
- W156942242 creator A5020717626 @default.
- W156942242 creator A5022750117 @default.
- W156942242 creator A5084193213 @default.
- W156942242 date "2011-11-01" @default.
- W156942242 modified "2023-09-23" @default.
- W156942242 title "[Prolactinoma treatment status in the cabergoline era]." @default.
- W156942242 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22036815" @default.
- W156942242 hasPublicationYear "2011" @default.
- W156942242 type Work @default.
- W156942242 sameAs 156942242 @default.
- W156942242 citedByCount "1" @default.
- W156942242 countsByYear W1569422422014 @default.
- W156942242 crossrefType "journal-article" @default.
- W156942242 hasAuthorship W156942242A5005698071 @default.
- W156942242 hasAuthorship W156942242A5016298609 @default.
- W156942242 hasAuthorship W156942242A5020717626 @default.
- W156942242 hasAuthorship W156942242A5022750117 @default.
- W156942242 hasAuthorship W156942242A5084193213 @default.
- W156942242 hasConcept C126322002 @default.
- W156942242 hasConcept C126894567 @default.
- W156942242 hasConcept C141071460 @default.
- W156942242 hasConcept C2778918492 @default.
- W156942242 hasConcept C2779064019 @default.
- W156942242 hasConcept C2779399171 @default.
- W156942242 hasConcept C2779832395 @default.
- W156942242 hasConcept C71315377 @default.
- W156942242 hasConcept C71924100 @default.
- W156942242 hasConceptScore W156942242C126322002 @default.
- W156942242 hasConceptScore W156942242C126894567 @default.
- W156942242 hasConceptScore W156942242C141071460 @default.
- W156942242 hasConceptScore W156942242C2778918492 @default.
- W156942242 hasConceptScore W156942242C2779064019 @default.
- W156942242 hasConceptScore W156942242C2779399171 @default.
- W156942242 hasConceptScore W156942242C2779832395 @default.
- W156942242 hasConceptScore W156942242C71315377 @default.
- W156942242 hasConceptScore W156942242C71924100 @default.
- W156942242 hasIssue "11" @default.
- W156942242 hasLocation W1569422421 @default.
- W156942242 hasOpenAccess W156942242 @default.
- W156942242 hasPrimaryLocation W1569422421 @default.
- W156942242 hasRelatedWork W1999012749 @default.
- W156942242 hasRelatedWork W2049638429 @default.
- W156942242 hasRelatedWork W2073158788 @default.
- W156942242 hasRelatedWork W2173645777 @default.
- W156942242 hasRelatedWork W2328010281 @default.
- W156942242 hasRelatedWork W2409617559 @default.
- W156942242 hasRelatedWork W2766126873 @default.
- W156942242 hasRelatedWork W2944276460 @default.
- W156942242 hasRelatedWork W2989591277 @default.
- W156942242 hasRelatedWork W2158987978 @default.
- W156942242 hasVolume "39" @default.
- W156942242 isParatext "false" @default.
- W156942242 isRetracted "false" @default.
- W156942242 magId "156942242" @default.
- W156942242 workType "article" @default.